|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Metformin does not improve survival in patients with hepatocellular carcinoma显示文摘AIM:To assess whether metformin,which has a chemopreventive effect in chronic liver disease,has any chemotherapeutic effect in hepatocellular carcinoma.METHODS:This was a retrospective study of 701 patients with newly diagnosed hepatocellular carcinoma(HCC)seen between January 2005 and June 2011 at Mayo Clinic,Rochester,Minnesota.This patient cohort was a part of the global HCC BRIDGE study,which is a large longitudinal study of HCC determining the realworld experience of HCC characteristics,management and patient outcomes.We defined significant metformin exposure as continuation of this agent at least 90d beyond diagnosis of HCC,and compared survival of diabetic patients on metformin to diabetic patients not on metformin and non-diabetics.RESULTS:Our cohort was 72.9%male,with a mean±SD age of 62.6±12.3 years.The most common etiologies of liver disease were hepatitis C(34%),alcoholic liver disease(29%),fatty liver disease(15%)and hepatitis B(9%).By univariate analysis,using diabetics not on metformin as the reference group,diabetic patients with HCC on metformin had no survival advantage,with a HR(95%CI)of 1.0(0.8-1.3).Non-diabetic HCC patients also did not appear to have a survival advantage as compared to diabetic HCC patients not on metformin,as demonstrated by a HR(95%CI)of1.1(0.7-1.7).Diabetics on metformin beyond 90 d after HCC diagnosis had a longer median survival at 34.2 mo,as compared to 25.5 mo among diabetic patients who were not on metformin or had discontinued metformin within 90 d after HCC diagnosis.This finding was likely due to potential survival bias among those who lived long enough to receive metformin.CONCLUSION:Although the literature suggests a chemotherapeutic effect in other malignancies,our study demonstrates no survival benefit to the use of metformin in diabetic patients with HCC. | Mamatha Bhat Roongruedee Chaiteerakij William S Harmsen Cathy D Schleck Ju Dong Yang Nasra H Giama Terry M Therneau Gregory J Gores Lewis R Roberts | 2014 | World Journal of Gastroenterology2014，20，42： | 11 |
| 2 | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models显示文摘AIM To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma(HCC) patients after liver transplant.METHODS BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein(AFP), Lens culinaris agglutinin-reactive AFP(AFP-L3), and des-gammacarboxyprothrombin(DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios(HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42(1.18-5.00), 1.86(0.98-3.52), and 2.83(1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48(1.15-1.91) and 1.59(1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45(1.06-1.98) and 1.38(1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65,0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant(S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter(S-LAD). | Nicha Wongjarupong Gabriela M Negron-Ocasio Roongruedee Chaiteerakij Benyam D Addissie Essa A Mohamed Kristin C Mara William S Harmsen J Paul Theobald Brian E Peters Joseph G Balsanek Melissa M Ward Nasra H Giama Sudhakar K Venkatesh Denise M Harnois Michael R Charlton Hiroyuki Yamada Alicia Algeciras-Schimnich Melissa R Snyder Terry M Therneau Lewis R Roberts | 2018 | World Journal of Gastroenterology2018，24，12： | 5 |
| 3 | Dietary approaches following endoscopic retrograde cholangiopancreatography: A survey of selected endoscopists显示文摘AIM: To describe the dietary recommendations of experienced endoscopists for patients who have undergone endoscopic retrograde cholangiopancreatography (ERCP) and the factors that influence these recommendations. METHODS: Selected U.S. endoscopists with ERCP experience were surveyed by e-mail. A questionnaire with three hypothetical ERCP cases of patients at low, medium and high risk for development of post-ERCP pancreatitis (PEP) was shown. For each scenario, respondents were asked to recommend a post-procedure diet and time to first oral intake. Respondents were also asked about the effect of various clinical factors on their recommendations, including risk of PEP.RESULTS: 97/187 selected ASGE members (51.9%) responded. When risk of PEP was either low, medium or high, 53%, 88% and 96% recommended a diet of clear liquids/NPO respectively, and 2%, 5% and 18% recommended delaying first oral intake until the following day. About 88% of respondents gave the same type of diet to patients at high as those with moderate-risk of PEP (P = 0.04). However, 37% and 43% of respondents gave different types of diet to patients at low vs moderate-risk and low-risk vs high-risk of PEP respectively (P < 0.001). No statistically significant associations were found regarding the effect of other clinical factors or respondent demographics.CONCLUSION: Most experienced endoscopists limit diet to NPO/clear liquids after ERCP for patients at high or moderate risk of post-ERCP pancreatitis. About half allow a low-fat or regular diet in patients at low risk. | Lincoln EVVC Ferreira Mark D Topazian William S Harmsen Alan R Zinsmeister Todd H Baron | 2010 | World Journal of Gastrointestinal Endoscopy2010，2，12： | 3 |
| 4 | Comparison of traditional phenotypie identification methods with partial 5'16S rRNA gene sequencing for species-level identification of nonfermenting gram- negative bacilli显示文摘 | Cloud J L Harmsen D Iwenet P C | 2010 | J Clin Microbiol2010，48，4： | 1 |
| 5 | 16S rDNA for diagnosing pat hogens:aliving tree显示文摘 | Harmsen D Karch H | 2004 | A SM News2004，70，： | 1 |
| 6 | Specific detection of Candida albicans and Candida tropicalis by fluorescent in situ hybrid ization with an 18S rRNA-targeted oligonucleotide probe 显示文摘 | Lischewski A Amann R I Harmsen D | 1996 | Microbiology1996，142，10： | 1 |
| 7 | Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk显示文摘 | CHAITEERAKIJ R YANG J D HARMSEN W S | 2013 | Hepatology2013，57，2： | 1 |
| 8 | Distribution of microorganisms in deep-sea hydrothermal vent chimneys investigated by whole cell hybridization and enrichment culture of thermophilic subpopulations显示文摘 | Harmsen H Prieur D Jeanthon C | | 0，，07： | 1 |
| 9 | Extra-large unce- mented hemispherical acetabular components for revision total hip arthroplasty 显示文摘 | Whaley A L Berry D J Harmsen W S | 2001 | J Bone Joint Surg Am2001，83，9： | 1 |
| 10 | Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology显示文摘 | Mellmann A Harmsen D Cummings CA | 2011 | PLoS One2011，6，22： | 1 |
| 11 | Typing of methicil- lin-resistant Staphylococcus aureus in a university hospitalsetting by using novel software for spa repeat determination and database management 显示文摘 | Harmsen D Claus H Witte W | 2003 | J Clin Microbiol2003，41，12： | 1 |
| 12 | Molecular ecology of microbes : A review of principles, pitfalls and true progress 显示文摘 | Akkerman A D L S Mirza M S Harmsen J M H | 1994 | FEMS Microbiol Rev1994，15，： | 1 |
| 13 | Reassessment of sequence-based targets for identification of bacillus species 显示文摘 | Blackwood K S Turenne C Y Harmsen D | 2004 | J Clin Microbiol2004，42，4： | 1 |
| 14 | Metastatic nonfunctioning pancreatic neu- roendocrine carcinoma to liver: surgical treatment and outcomes 显示文摘 | Cusati D Zhang L Harmsen WS | 2012 | J Am Coil Surg2012，215，1： | 1 |
| 15 | Mem- brane fouling and process performance of forward osmosis membranes on activated sludge 显示文摘 | Cornelissen E R Harmsen D de Korte K F | 2008 | J Membrane Sci2008，319，12： | 1 |
| 16 | Membrane fouling andprocess performance of forward osmosis membranes on activated sludge显示文摘 | Comelissen E Harmsen D De Korte K | 2008 | Journal of Membrane Science2008，319，1： | 1 |
| 17 | Population dynamics of propionate-oxidizing bacteria under methanogenic and sulfidogenic conditions in anaerobic granular sludge 显示文摘 | Akkermans A D L Stams AJM | 1996 | Appl Environ Microbiol1996，62，： | 1 |
| 18 | Whole-genome-based Mycobacterium tuberculosis surveillance: a standardized, portable, and expandable approach 显示文摘 | Kohl TA Diel R Harmsen D | 2014 | J Clin Microbiol2014，52，7： | 1 |
| 19 | Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4outbreak by rapid next generation sequencing technology显示文摘 | Mellmann A Harmsen D Cummings CA | 2011 | PloS one2011，6，22： | 1 |
| 20 | Metastatic nonfunctioning pancreatic neuroendocrine carcinoma to liver:surgical treatment and outcomes显示文摘 | CUSATI D ZHANG L HARMSEN W S | 2012 | J Am Coll Surg2012，215，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员